Cellnovo (EPA:CLNV) said today that it has filed for 510(k) clearance from the FDA for its diabetes management system.
Paris-based Cellnovo touts its system as the 1st mobile, connected diabetes management system. Tubeless and compact, the company’s insulin pump has a mobile touchscreen controller with an integrated blood glucose meter. Data from insulin injections and blood-glucose levels are automatically transmitted using Cellnovo’s connected system, allowing healthcare professionals to continually monitor the patient’s condition in real time. The device offered superior accuracy in insulin delivery when compared to other compact wearable systems in a peer-reviewed publication, according to the company.
Get the full story at our sister site, Drug Delivery Business News
The post Cellnovo files 510(k) for connected diabetes management system appeared first on MassDevice.